Phase I study of TH-302, investigational hypoxia-targeted drug, in combination with sunitinib.

被引：0

作者：

Starodub, Alexander

Milhem, Mohammed M.

Pennington, Kenneth Lee

Kio, Ebenezer A.

Bruetman, Daniel

Thorne, Tracy

Hickingbottom, Barbara

Kroll, Stew

机构：

[1] Indiana Univ, Hlth Goshen Ctr Canc Care, Goshen, IN USA

[2] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA

[3] Goshen Ctr Canc Care, Goshen, IN USA

[4] Ctr Canc Care Goshen, Goshen, IN USA

[5] Threshold Pharmaceut Inc, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e15557

引用

页数：1

共 50 条

[21] COMPLETE PHASE IB STUDY OF TH-302 IN COMBINATION WITH GEMCITABINE (G), DOCETAXEL (D) OR PEMETREXED (P)
Borad, M.
Mita, A.
Infante, J.
Chiorean, E. G.
Vlahovic, G.
Armstrong, A.
Traynor, A. M.
Schelman, W.
Langmuir, V.
Eng, C.
ANNALS OF ONCOLOGY, 2010, 21 : 172 - 172
[22] HYPOXIA ACTIVATED EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, A MULTICENTER PHASE II STUDY
Brenner, Andrew
Reardon, David
Wen, Patrick
Fox, Peter
Huang, Shiliang
Muzi, Mark
Liu, Yichu
Lee, Eudocia
NEURO-ONCOLOGY, 2017, 19 : 21 - 21
[23] DUAL PHASE I/II STUDY OF TH-302 AND BEVACIZUMAB INRECURRENT GLIOBLASTOMA FOLLOWING BEVACIZUMAB FAILURE
Brenner, Andrew
Sun, Jessica
Floyd, John
Hart, Charles
Eng, Clarence
Fichtel, Lisa
Gruslova, Aleksandra
Lodi, Alessia
Tiziani, Stefano
NEURO-ONCOLOGY, 2013, 15 : 101 - 102
[24] Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
Chawla, Sant P.
Cranmer, Lee D.
Van Tine, Brian A.
Reed, Damon R.
Okuno, Scott H.
Butrynski, James E.
Adkins, Douglas R.
Hendifar, Andrew E.
Kroll, Stew
Ganjoo, Kristen N.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (29) : 3299 - +
[25] Japanese phase I trial of hypoxia-activated prodrug evofosfamide (TH-302) as monotherapy in patients with solid tumors or in combination with gemcitabine in patients with advanced pancreatic cancer
Mitsunaga, S.
Takahashi, H.
Doi, T.
Johne, A.
Wang, J.
Shimizu, A.
Ikeda, M.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S436 - S436
[26] A DUAL PHASE I/II STUDY OF TH-302 AND BEVACIZUMAB IN RESECTABLE RECURRENT GLIOBLASTOMA FOLLOWING BEVACIZUMAB FAILURE
Zuniga, R. M.
Sun, J.
Floyd, J. R.
Yerragudi, S. R.
Hart, C.
Eng, C.
Brenner, A. J.
ANNALS OF ONCOLOGY, 2012, 23 : 150 - 151
[27] Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC).
Sankhala, K. K.
Chiorean, E. G.
Armstrong, A. J.
Borad, M. J.
Traynor, A. M.
Gadgeel, S. M.
Langmuir, V. K.
Eng, C.
Kroll, S.
Burris, H.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[28] Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
Weiss, Glen J.
Infante, Jeffrey R.
Chiorean, E. Gabriela
Borad, Mitesh J.
Bendell, Johanna C.
Molina, Julian R.
Tibes, Raoul
Ramanathan, Ramesh K.
Lewandowski, Karen
Jones, Suzanne F.
Lacouture, Mario E.
Langmuir, Virginia K.
Lee, Hank
Kroll, Stew
Burris, Howard A., III
CLINICAL CANCER RESEARCH, 2011, 17 (09) : 2997 - 3004
[29] A phase II dose expansion of TH-302 in combination with doxorubicin in soft-tissue sarcoma.
Cranmer, L. D.
Ganjoo, K. N.
Adkins, D.
Reed, D. R.
Okuno, S. H.
Butrynski, J. E.
Rushing, D. A.
Lorente, G. A.
Kroll, S.
Chawla, S. P.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[30] Hypoxia activated pro-drug TH-302 induces hypoxia-dependent anti-leukemia activity in vitro and in vivo
Benito, Juliana M.
Lu, Hongbo
Shi, Yuexi
Jacamo, Rodrigo O.
McQueen, Teresa J.
Konoplev, Sergej
Bueso-Ramos, Carlos
Zweidler-McKay, Patrick
Handisides, Damian
Hart, Charles P.
Andreeff, Michael
Konopleva, Marina
CANCER RESEARCH, 2012, 72

← 1 2 3 4 5 →